VA-SES
3.6.2021 08:52:10 CEST | Business Wire | Press release
SES Government Solutions (SES GS), a wholly-owned subsidiary of SES, and Isotropic Systems, a leading developer of transformational broadband terminal technologies, announce the successful completion of the first of two milestone next-generation antenna trials with the U.S. Military aimed at unleashing unprecedented information distribution to warfighters across the battlefield.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210602006167/en/
The U.S. Air Force and U.S. Army, through the innovative Defense Experimentation Using Commercial Space Internet (DEUCSI) program, are evaluating the ability of Isotropic Systems’ optical beamforming antenna to enable frontline armed forces to access high-speed, real-time data simultaneously over multiple commercial and military satellites.
First phase dual-beam tests conducted at the Harwell Science, Technology and Innovation Campus near Oxford, UK, have successfully demonstrated transformational optics at the core of Isotropic Systems’ multi-beam terminal that are fully capable of linking with multiple satellites at the same time.
Over-the-air (OTA) trials conducted at an SES teleport in Port St. Lucie, Florida, also part of phase one, have verified the Isotropic Systems’ high-performance multi-beam platform meets military requirements to acquire and track SES’ O3b MEO satellites.
Phase two trials will test Isotropic Systems’ latest antenna prototype over links with SES satellites in geostationary orbit (GEO) and medium earth orbit (MEO), demonstrating seamless satellite-to-satellite transitions and a redundant, resilient leap in wartime communications.
The DEUCSI trials will wrap up in 2021, ahead of the commercial launch of Isotropic Systems’ optical multi-beam antenna production scheduled for 2022, and in time to support SES’ new high-throughput MEO constellation satellites coming online, the groundbreaking O3b mPOWER system.
“The armed forces and defense agencies are incredibly good at acquiring actionable information, but they run into bottlenecks when they try to distribute that mission-critical data over single beam parabolic antennas and other outdated infrastructure,” said Scott Sprague, Isotropic Systems CCO. “These milestone trials with the U.S. Army and Air Force are successfully demonstrating the multi-beam, multi-orbit connectivity and capabilities our high-performance terminals will put in the hands of frontline warfighters and decision makers across the government sector and battlespace.”
“Next-gen satellites and constellations need equally robust and resilient terminals and ground infrastructure to meet the government’s ’Fighting SATCOM’ vision,” said Pete Hoene, President and CEO of SES Government Solutions, Brigadier General, USAF (Ret.). “Interoperability and multi-orbit capabilities are essential to achieving this vision, and these collaborative trials with the armed forces demonstrate how Isotropic Systems’ multi-beam antenna can successfully deliver robust connectivity across our vast MEO and GEO fleet. Each successful phase is a prime example of how the government and commercial partners can develop capabilities in parallel, which is especially important to us as we ready to launch our O3b mPOWER constellation and SES-17 satellite this year.
“Without affecting the main communications link, the Isotropic Systems multi-beam terminal can use a second or third link to evaluate the environment to preemptively decide the best routing option at any given time to maximize performance,” explained Brian Billman, Vice President of Product Management for Isotropic Systems. “That’s the level of differentiating capabilities our terminal roadmap leads to as a result of these important trials with the U.S. military.”
For further information please contact:
About SES Government Solutions
SES Government Solutions (SES GS) is a wholly-owned subsidiary of SES, the leader in global content connectivity solutions. SES GS operates under a proxy board allowing them to provide services through contracts with the U.S. Government, including classified work. SES GS is exclusively focused on meeting the satellite communications needs of the U.S. Government. Leveraging more than four decades of experience in the government SATCOM market, SES GS offers robust and secure end-to-end satellite communications solutions. Further information can be found at www.ses-gs.com .
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,200 channels and has an unparalleled reach of 361 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com .
About Isotropic Systems
Isotropic Systems is developing the world’s first multi-service, high-bandwidth, low power, fully integrated high throughput terminals designed to support the satellite industry to 'reach beyond' traditional markets and acquire new customers with a full suite of high throughput services. The company’s team of industry experts and scientists has pioneered several firsts in satellite terminal design resulting in a line of terminals that are customizable to meet the performance, cost and power requirements of countless applications – from the most complex government defense systems and mobile backhaul solutions capable of extending 5G, to next-gen connected experiences aboard commercial airliners, cruise ships, offshore rigs, and even small fishing boats at sea. Isotropic Systems’ Series A funding was led by Boeing to advance space-based connectivity. Further information is available at www.isotropicsystems.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210602006167/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release
Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom